[CIS PIDD] [cis-pidd] ADA2 deficiency - Infliximab dosage

[CIS-PIDD]

Dear Fabian,

Marco Gattorno just reported 15 DADA2 patients with an inflammatory phenotype (stroke/PAN...). 
11/15 were treated with etanercept (none with infliximab), 10/11 had a complete response, 1 had a partial response.

Caorsi R, et al. Ann Rheum Dis 2017;0:1–9
http://dx.doi.org/10.1136/annrheumdis-2016-210802 <http://dx.doi.org/10.1136/annrheumdis-2016-210802>



Stefano Volpi, MD, PhD
IRCCS Istituto G. Gaslini, Italy
stefanovolpi at gaslini.org <mailto:stefanovolpi at gaslini.org>



> On 16 May 2017, at 20:15, CIS-PIDD <cis-pidd at lists.clinimmsoc.org <mailto:cis-pidd at lists.clinimmsoc.org>> wrote:
> 
> Dear Fabian,
> 
> Why would you use infliximab as opposed to etanercept? 
> 
> Isabelle Meyts, UZ Leuven
> 
> 
> 
> 
> Op 16-mei-2017 om 17:00 heeft CIS-PIDD <cis-pidd at lists.clinimmsoc.org <mailto:cis-pidd at lists.clinimmsoc.org>> het volgende geschreven:
> 
>> Dear all,
>>  
>> I am planning to treat an ADA2 deficient patient with Infliximab and would like to know the dosage and the dosing intervall already used sucessfully.
>> Is it 5mg/kg at week 0, 2, 6 and thereafter every 8 weeks?
>>  
>> Thank you and best regards,
>>  
>> Fabian
>>  
>>  
>> Fabian Hauck, MD, PhD
>>  
>> Head Immunodeficiency Unit and Immunological Diagnostics Laboratoy
>> Pediatrics / Pediatric Hematology and Oncology / Immunology (DGfI)
>>  
>> Dr. von Hauner Children’s Hospital
>> Klinikum der Universität München 
>> Lindwurmstr. 4, 80337 München
>> Germany
>>  
>> Tel.: +49 89 4400-53931
>> Fax: +49 89 4400-53964
>> E-Mail: fabian.hauck at med.uni-muenchen.de <mailto:fabian.hauck at med.uni-muenchen.de>
>>  
>>  
>> www.klinikum.uni-muenchen.de <http://www.klinikum.uni-muenchen.de/>
>>  
>> <image001.png>
>>  
>> Das Klinikum der Universität München ist eine Anstalt des öffentlichen Rechts (AöR)
>> The Klinikum der Universität München is an Institution under Public Law
>>  
>>  
>>  
>> 
>> ---
>> 
>> You are currently subscribed to cis-pidd as: Isabelle.Meyts at uzleuven.be <mailto:Isabelle.Meyts at uzleuven.be>.
>> 
>> To unsubscribe click here: http://cts.dundee.net/u?id=96396636.15f0ef7c3f65602e498cc8265c1ae62d&n=T&l=cis-pidd&o=4376767 <http://cts.dundee.net/u?id=96396636.15f0ef7c3f65602e498cc8265c1ae62d&n=T&l=cis-pidd&o=4376767>
>> (It may be necessary to cut and paste the above URL if the line is broken)
>> 
>> or send a blank email to leave-4376767-96396636.15f0ef7c3f65602e498cc8265c1ae62d at lyris.dundee.net <mailto:leave-4376767-96396636.15f0ef7c3f65602e498cc8265c1ae62d at lyris.dundee.net>---
> 
> You are currently subscribed to cis-pidd as: stefanovolpi at gaslini.org <mailto:stefanovolpi at gaslini.org>.
> 
> To unsubscribe click here: http://cts.dundee.net/u?id=102315137.92fe7cc48055452f721d8ed3f3d53441&n=T&l=cis-pidd&o=4377143 <http://cts.dundee.net/u?id=102315137.92fe7cc48055452f721d8ed3f3d53441&n=T&l=cis-pidd&o=4377143>
> (It may be necessary to cut and paste the above URL if the line is broken)
> 
> or send a blank email to leave-4377143-102315137.92fe7cc48055452f721d8ed3f3d53441 at lyris.dundee.net <mailto:leave-4377143-102315137.92fe7cc48055452f721d8ed3f3d53441 at lyris.dundee.net>

---
You are currently subscribed to cis-pidd as: pagid at list.clinimmsoc.org.
To unsubscribe click here: http://cts.dundee.net/u?id=96396833.5a9591ccd1e327fe6bc4d1543298c482&n=T&l=cis-pidd&o=4382701
or send a blank email to leave-4382701-96396833.5a9591ccd1e327fe6bc4d1543298c482 at lyris.dundee.net
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://pairlist7.pair.net/pipermail/pagid/attachments/20170519/fd785f29/attachment-0001.html>